歩行の凍結市場調査レポート:2030年までの予測Freeze of Gait Market Research Report Forecast till 2030 歩行の凍結市場調査レポート:2030年までの予測 市場概要 歩行凍結市場は予測期間中に4.86%の複合年間成長率(CAGR)を示すと予測される。歩行凍結の普及が進んでいることが、市場拡大の重要な原動力の一つと... もっと見る
サマリー歩行の凍結市場調査レポート:2030年までの予測市場概要 歩行凍結市場は予測期間中に4.86%の複合年間成長率(CAGR)を示すと予測される。歩行凍結の普及が進んでいることが、市場拡大の重要な原動力の一つとなっています。 パーキンソン病は、中枢触覚骨格の問題であり、固さや震え、協調性やバランス感覚の問題など、不注意や乱暴な方向転換を引き起こす。これらの後遺症は一般的に着実に始まり、長期的には一度消滅する。歩行や会話に支障をきたすこともある。歩行の凍結(霧)は、おそらくパーキンソン病(PD)患者の最も衰弱させる運動後遺症の一つである。歩行凍結は、予期せぬ歩行開始不能や歩行不能を引き起こす特異な歩行計画である。 ネイチャー・ジャーナル』誌に掲載されたデータによると、2022年にはパーキンソン病患者の約半数、最先端のパーキンソン病患者の80%が霧の影響を受けるという。パーキンソン財団によると、現在米国では約100万人がパーキンソン病(PD)と共に生活しており、2030年までにこの数は120万人に増加すると調査されている。 市場区分 歩行凍結市場は、脳深部刺激、ウェアラブル技術、歩行補助具、経口ドパミン薬、その他の製品がタイプ別に分類されている。 歩行凍結市場は、診療所、病院、その他の施設を含むエンドユーザーによって区分される。 地域別洞察 北米の歩行凍結市場は、2022年には4億8,000万米ドルに達し、レビュー期間中の年平均成長率は5.17%になると予測されています。これは、重要な参加者のビジネスプレゼンス、FDAのお墨付きの上昇、処方と治療法に関する意識の拡大、この地域におけるパーキンソン病の蔓延の高まりが、予測期間中の地域市場の発展を後押ししているためです。 欧州の歩行凍結市場は、医療利用の増加、最先端の治療薬への関心の高まり、老年人口の拡大が、パーキンソン病に関連する歩行凍結の賭けにつながり、欧州地域における歩行凍結の開発を促進するため、パイの2番目に大きな部分を占めると思われます。 病気発見のためのトレンド設定技術革新への開放性、歩行凍結に傾倒する老年人口の増加が、強力な治療と治療薬への関心を高め、歩行凍結に対する心構えを拡大させています。 アジア太平洋地域の歩行凍結市場は、2023年から2030年にかけて年平均成長率6.03%で発展すると考えられている。これは、臨床オフィスの増加、凍結歩行治療に対する政府の推進力の拡大、凍結歩行に関連するパーキンソン病の膨大な患者プールの存在などの要素が、アジア太平洋地域の凍結歩行市場の発展に大きく影響しているためです。その他の地域には、中東、アフリカ、ラテンアメリカが含まれます。 市場概要 歩行凍結市場の主要企業には、Teva Pharmaceuticals(イスラエル)、Sun Pharmaceutical Industries Ltd(インド)、Viatris Inc(米国)、Gondola Medical Technologies SA(スイス)、Gyenno Technologies Co.(中国)、Beats Medical Limited (アイルランド)、Agilitas (オーストラリア)、Walk with Path (Vesterbro)、MedEXO Robotics (香港)、Ustep (米国)。 目次TABLE OF CONTENTS1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 MARKET STRUCTURE 2.5 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING PREVALENCE OF PARKINSON’S DISEASE AND OTHER RELATED DISEASES 4.2.2 GROWING GERIATRIC POPULATION 4.2.3 INCREASING INVESTMENT IN R&D 4.3 RESTRAINTS 4.3.1 STRINGENT REGULATORY REQUIREMENTS 4.4 OPPORTUNITIES 4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D AND DESIGNING 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION, MARKETING, AND SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF BUYERS 5.2.3 THREAT OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTES 5.2.5 INTENSITY OF RIVALRY 5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET 5.3.1 OVERVIEW 5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS 5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS 5.3.4 IMPACT ON ELECTIVE PROCEDURE 5.3.5 IMPACT ON SUPPLY CHAIN 6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE 6.1 OVERVIEW 6.2 ORAL DOPAMINERGIC MEDICATION 6.3 WEARABLE AND WALKING AID DEVICES 6.4 DEEP BRAIN STIMULATION 6.5 OTHERS 7 GLOBAL FREEZE OF GAIT MARKET, BY END USER 7.1 OVERVIEW 7.2 HOSPITALS 7.3 CLINICS 7.4 OTHERS 8 GLOBAL FREEZE OF GAIT MARKET, BY REGION 8.1 NORTH AMERICA 8.1.1 US 8.1.2 CANADA 8.2 EUROPE 8.2.1 GERMANY 8.2.2 FRANCE 8.2.3 UK 8.2.4 ITALY 8.2.5 SPAIN 8.2.6 REST OF EUROPE 8.3 ASIA-PACIFIC 8.3.1 CHINA 8.3.2 INDIA 8.3.3 JAPAN 8.3.4 AUSTRALIA 8.3.5 SOUTH KOREA 8.3.6 REST OF ASIA-PACIFIC 8.4 REST OF THE WORLD 8.4.1 MIDDLE EAST 8.4.2 AFRICA 8.4.3 LATIN AMERICA 9 COMPETITIVE LANDSCAPE 9.1 OVERVIEW 9.2 COMPETITIVE BENCHMARKING 9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 9.5.1 PARTNERSHIP & COLLABORATIONS 9.6 MAJOR PLAYERS SALES ANALYSIS 9.6.1 SALES & OPERATING INCOME 9.7 MAJOR PLAYERS R&D ANALYSIS 10 COMPANY PROFILES 10.1 VIATRIS INC. 10.1.1 COMPANY OVERVIEW 10.1.2 FINANCIAL OVERVIEW 10.1.3 PRODUCTS OFFERED 10.1.4 KEY DEVELOPMENTS 10.1.5 SWOT ANALYSIS 10.1.6 KEY STRATEGIES 10.2 GONDOLA MEDICAL TECHNOLOGIES SA 10.2.1 COMPANY OVERVIEW 10.2.2 FINANCIAL OVERVIEW 10.2.3 PRODUCTS OFFERED 10.2.4 KEY DEVELOPMENTS 10.2.5 SWOT ANALYSIS 10.2.6 KEY STRATEGIES 10.3 USTEP 10.3.1 COMPANY OVERVIEW 10.3.2 FINANCIAL OVERVIEW 10.3.3 PRODUCTS OFFERED 10.3.4 KEY DEVELOPMENTS 10.3.5 KEY STRATEGIES 10.4 GYENNO TECHNOLOGIES CO., LTD. 10.4.1 COMPANY OVERVIEW 10.4.2 FINANCIAL OVERVIEW 10.4.3 PRODUCTS OFFERED 10.4.4 KEY DEVELOPMENTS 10.4.5 SWOT ANALYSIS 10.4.6 KEY STRATEGIES 10.5 MEDEXO ROBOTICS 10.5.1 COMPANY OVERVIEW 10.5.2 FINANCIAL OVERVIEW 10.5.3 PRODUCTS OFFERED 10.5.4 KEY DEVELOPMENTS 10.5.5 KEY STRATEGIES 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 10.6.1 COMPANY OVERVIEW 10.6.2 FINANCIAL ANALYSIS 10.6.3 PRODUCTS OFFERED 10.6.4 KEY DEVELOPMENTS 10.6.5 SWOT ANALYSIS 10.6.6 KEY STRATEGIES 10.7 SUN PHARMACEUTICAL INDUSTRIES LTD 10.7.1 COMPANY OVERVIEW 10.7.2 FINANCIAL OVERVIEW 10.7.3 PRODUCTS OFFERED 10.7.4 KEY DEVELOPMENTS 10.7.5 SWOT ANALYSIS 10.7.6 KEY STRATEGIES 10.8 WALK WITH PATH 10.8.1 COMPANY OVERVIEW 10.8.2 FINANCIAL OVERVIEW 10.8.3 PRODUCTS OFFERED 10.8.4 KEY DEVELOPMENTS 10.8.5 KEY STRATEGIES 10.9 BEATS MEDICAL LIMITED 10.9.1 COMPANY OVERVIEW 10.9.2 FINANCIAL OVERVIEW 10.9.3 PRODUCTS OFFERED 10.9.4 KEY DEVELOPMENTS 10.9.5 KEY STRATEGIES 10.10 AGILITAS 10.10.1 COMPANY OVERVIEW 10.10.2 FINANCIAL OVERVIEW 10.10.3 PRODUCTS OFFERED 10.10.4 KEY DEVELOPMENTS 10.10.5 KEY STRATEGIES 11 APPENDIX 11.1 REFERENCES 11.2 RELATED REPORTS 図表リストLIST OF TABLESTABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019–2030 (USD MILLION) TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019–2030 (USD MILLION) TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2030 (USD MILLION) TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION) TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019–2030 (USD MILLION) TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019–2030 (USD MILLION) TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION) TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019–2030 (USD MILLION) TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION) TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION) TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET TABLE 65 PARTNERSHIP & COLLABORATIONS TABLE 66 VIATRIS INC.: PRODUCTS OFFERED TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS TABLE 69 USTEP: PRODUCTS OFFERED TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED TABLE 74 WALK WITH PATH: PRODUCTS OFFERED TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED TABLE 76 AGILITAS: PRODUCTS OFFERED
SummaryFreeze of Gait Market Research Report Forecast till 2030 Table of ContentsTABLE OF CONTENTS1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 2.2 SCOPE OF THE STUDY 2.3 RESEARCH OBJECTIVE 2.4 MARKET STRUCTURE 2.5 ASSUMPTIONS & LIMITATIONS 3 RESEARCH METHODOLOGY 3.1 DATA MINING 3.2 SECONDARY RESEARCH 3.3 PRIMARY RESEARCH 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 3.5 FORECASTING TECHNIQUES 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 3.6.1 BOTTOM-UP APPROACH 3.6.2 TOP-DOWN APPROACH 3.7 DATA TRIANGULATION 3.8 VALIDATION 4 MARKET DYNAMICS 4.1 OVERVIEW 4.2 DRIVERS 4.2.1 INCREASING PREVALENCE OF PARKINSON’S DISEASE AND OTHER RELATED DISEASES 4.2.2 GROWING GERIATRIC POPULATION 4.2.3 INCREASING INVESTMENT IN R&D 4.3 RESTRAINTS 4.3.1 STRINGENT REGULATORY REQUIREMENTS 4.4 OPPORTUNITIES 4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 5.1.1 R&D AND DESIGNING 5.1.2 MANUFACTURING 5.1.3 DISTRIBUTION, MARKETING, AND SALES 5.1.4 POST-SALES MONITORING 5.2 PORTER'S FIVE FORCES MODEL 5.2.1 BARGAINING POWER OF SUPPLIERS 5.2.2 BARGAINING POWER OF BUYERS 5.2.3 THREAT OF NEW ENTRANTS 5.2.4 THREAT OF SUBSTITUTES 5.2.5 INTENSITY OF RIVALRY 5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET 5.3.1 OVERVIEW 5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS 5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS 5.3.4 IMPACT ON ELECTIVE PROCEDURE 5.3.5 IMPACT ON SUPPLY CHAIN 6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE 6.1 OVERVIEW 6.2 ORAL DOPAMINERGIC MEDICATION 6.3 WEARABLE AND WALKING AID DEVICES 6.4 DEEP BRAIN STIMULATION 6.5 OTHERS 7 GLOBAL FREEZE OF GAIT MARKET, BY END USER 7.1 OVERVIEW 7.2 HOSPITALS 7.3 CLINICS 7.4 OTHERS 8 GLOBAL FREEZE OF GAIT MARKET, BY REGION 8.1 NORTH AMERICA 8.1.1 US 8.1.2 CANADA 8.2 EUROPE 8.2.1 GERMANY 8.2.2 FRANCE 8.2.3 UK 8.2.4 ITALY 8.2.5 SPAIN 8.2.6 REST OF EUROPE 8.3 ASIA-PACIFIC 8.3.1 CHINA 8.3.2 INDIA 8.3.3 JAPAN 8.3.4 AUSTRALIA 8.3.5 SOUTH KOREA 8.3.6 REST OF ASIA-PACIFIC 8.4 REST OF THE WORLD 8.4.1 MIDDLE EAST 8.4.2 AFRICA 8.4.3 LATIN AMERICA 9 COMPETITIVE LANDSCAPE 9.1 OVERVIEW 9.2 COMPETITIVE BENCHMARKING 9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET 9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET 9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 9.5.1 PARTNERSHIP & COLLABORATIONS 9.6 MAJOR PLAYERS SALES ANALYSIS 9.6.1 SALES & OPERATING INCOME 9.7 MAJOR PLAYERS R&D ANALYSIS 10 COMPANY PROFILES 10.1 VIATRIS INC. 10.1.1 COMPANY OVERVIEW 10.1.2 FINANCIAL OVERVIEW 10.1.3 PRODUCTS OFFERED 10.1.4 KEY DEVELOPMENTS 10.1.5 SWOT ANALYSIS 10.1.6 KEY STRATEGIES 10.2 GONDOLA MEDICAL TECHNOLOGIES SA 10.2.1 COMPANY OVERVIEW 10.2.2 FINANCIAL OVERVIEW 10.2.3 PRODUCTS OFFERED 10.2.4 KEY DEVELOPMENTS 10.2.5 SWOT ANALYSIS 10.2.6 KEY STRATEGIES 10.3 USTEP 10.3.1 COMPANY OVERVIEW 10.3.2 FINANCIAL OVERVIEW 10.3.3 PRODUCTS OFFERED 10.3.4 KEY DEVELOPMENTS 10.3.5 KEY STRATEGIES 10.4 GYENNO TECHNOLOGIES CO., LTD. 10.4.1 COMPANY OVERVIEW 10.4.2 FINANCIAL OVERVIEW 10.4.3 PRODUCTS OFFERED 10.4.4 KEY DEVELOPMENTS 10.4.5 SWOT ANALYSIS 10.4.6 KEY STRATEGIES 10.5 MEDEXO ROBOTICS 10.5.1 COMPANY OVERVIEW 10.5.2 FINANCIAL OVERVIEW 10.5.3 PRODUCTS OFFERED 10.5.4 KEY DEVELOPMENTS 10.5.5 KEY STRATEGIES 10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 10.6.1 COMPANY OVERVIEW 10.6.2 FINANCIAL ANALYSIS 10.6.3 PRODUCTS OFFERED 10.6.4 KEY DEVELOPMENTS 10.6.5 SWOT ANALYSIS 10.6.6 KEY STRATEGIES 10.7 SUN PHARMACEUTICAL INDUSTRIES LTD 10.7.1 COMPANY OVERVIEW 10.7.2 FINANCIAL OVERVIEW 10.7.3 PRODUCTS OFFERED 10.7.4 KEY DEVELOPMENTS 10.7.5 SWOT ANALYSIS 10.7.6 KEY STRATEGIES 10.8 WALK WITH PATH 10.8.1 COMPANY OVERVIEW 10.8.2 FINANCIAL OVERVIEW 10.8.3 PRODUCTS OFFERED 10.8.4 KEY DEVELOPMENTS 10.8.5 KEY STRATEGIES 10.9 BEATS MEDICAL LIMITED 10.9.1 COMPANY OVERVIEW 10.9.2 FINANCIAL OVERVIEW 10.9.3 PRODUCTS OFFERED 10.9.4 KEY DEVELOPMENTS 10.9.5 KEY STRATEGIES 10.10 AGILITAS 10.10.1 COMPANY OVERVIEW 10.10.2 FINANCIAL OVERVIEW 10.10.3 PRODUCTS OFFERED 10.10.4 KEY DEVELOPMENTS 10.10.5 KEY STRATEGIES 11 APPENDIX 11.1 REFERENCES 11.2 RELATED REPORTS List of Tables/GraphsLIST OF TABLESTABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019–2030 (USD MILLION) TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019–2030 (USD MILLION) TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2030 (USD MILLION) TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION) TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019–2030 (USD MILLION) TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019–2030 (USD MILLION) TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2030 (USD MILLION) TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019–2030 (USD MILLION) TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION) TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2030 (USD MILLION) TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2030 (USD MILLION) TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2030 (USD MILLION) TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2030 (USD MILLION) TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2030 (USD MILLION) TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2030 (USD MILLION) TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2030 (USD MILLION) TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET TABLE 65 PARTNERSHIP & COLLABORATIONS TABLE 66 VIATRIS INC.: PRODUCTS OFFERED TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS TABLE 69 USTEP: PRODUCTS OFFERED TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED TABLE 74 WALK WITH PATH: PRODUCTS OFFERED TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED TABLE 76 AGILITAS: PRODUCTS OFFERED
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Market Research Future社の医療分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問Market Research Future社はどのような調査会社ですか?マーケットリサーチフューチャー(Market Research Future)は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。 下記分野については、分野毎に専... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |